FI108358B - Trichoderman transformointi - Google Patents

Trichoderman transformointi Download PDF

Info

Publication number
FI108358B
FI108358B FI871908A FI871908A FI108358B FI 108358 B FI108358 B FI 108358B FI 871908 A FI871908 A FI 871908A FI 871908 A FI871908 A FI 871908A FI 108358 B FI108358 B FI 108358B
Authority
FI
Finland
Prior art keywords
trichoderma
gene
strain
vector system
plasmid
Prior art date
Application number
FI871908A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI871908L (fi
FI871908A0 (fi
Inventor
Mogens Trier Hansen
Anu Marjukka Harkki
Jonathan Kenneth Knowles
Kaisu Milja Helena Nevalainen
Merja Elisa Penttilo
Original Assignee
Altia Group Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10597131&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI108358(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altia Group Oy filed Critical Altia Group Oy
Publication of FI871908A0 publication Critical patent/FI871908A0/fi
Publication of FI871908L publication Critical patent/FI871908L/fi
Application granted granted Critical
Publication of FI108358B publication Critical patent/FI108358B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2428—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6483—Chymosin (3.4.23.4), i.e. rennin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01091—Cellulose 1,4-beta-cellobiosidase (3.2.1.91)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23004—Chymosin (3.4.23.4), i.e. rennin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
FI871908A 1986-04-30 1987-04-29 Trichoderman transformointi FI108358B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8610600 1986-04-30
GB868610600A GB8610600D0 (en) 1986-04-30 1986-04-30 Transformation of trichoderma

Publications (3)

Publication Number Publication Date
FI871908A0 FI871908A0 (fi) 1987-04-29
FI871908L FI871908L (fi) 1987-10-31
FI108358B true FI108358B (fi) 2002-01-15

Family

ID=10597131

Family Applications (1)

Application Number Title Priority Date Filing Date
FI871908A FI108358B (fi) 1986-04-30 1987-04-29 Trichoderman transformointi

Country Status (10)

Country Link
EP (1) EP0244234B2 (fr)
JP (2) JP2702924B2 (fr)
AT (1) ATE91714T1 (fr)
DE (1) DE3786592T3 (fr)
DK (1) DK175814B1 (fr)
ES (1) ES2056817T5 (fr)
FI (1) FI108358B (fr)
GB (1) GB8610600D0 (fr)
IE (1) IE60428B1 (fr)
NO (1) NO871785L (fr)

Families Citing this family (571)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5320960A (en) * 1992-04-03 1994-06-14 Genencor International, Inc. Method of preparing solution enriched in xylanase using low molecular weight alcohol, organic salt and inorganic salt
US5298405A (en) * 1986-04-30 1994-03-29 Alko Limited Enzyme preparations with recombinantly-altered cellulose profiles and methods for their production
US5780292A (en) * 1987-04-29 1998-07-14 Alko Group Ltd. Production of phytate degrading enzymes in trichoderma
US5610034A (en) * 1987-04-29 1997-03-11 Alko Group Ltd. Immunoglobulin production by trichoderma
WO1989009259A1 (fr) * 1988-03-24 1989-10-05 Novo-Nordisk A/S Preparation de cellulase
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
CA1333777C (fr) 1988-07-01 1995-01-03 Randy M. Berka Champignons filamenteux deficients en proteinase aspartique
CA1341226C (fr) * 1988-08-16 2001-05-01 Wim Van Hartingsveldt Replacement de gene comme outil de construction de souches d'aspergillus
FR2649120B1 (fr) * 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5120463A (en) * 1989-10-19 1992-06-09 Genencor International, Inc. Degradation resistant detergent compositions based on cellulase enzymes
US5688290A (en) * 1989-10-19 1997-11-18 Genencor International, Inc. Degradation resistant detergent compositions based on cellulase enzymes
US5837515A (en) * 1990-05-16 1998-11-17 Alko-Yhtiot Oy Enzyme preparations and methods for their production
FI903443A7 (fi) * 1990-07-06 1992-01-07 Valtion Teknillinen Framstaellning av lackas genom rekombinantorganismer.
CA2084189A1 (fr) * 1990-07-16 1992-01-17 Alko Group Limited Production d'immunoglobuline par trichoderma
US5290474A (en) * 1990-10-05 1994-03-01 Genencor International, Inc. Detergent composition for treating cotton-containing fabrics containing a surfactant and a cellulase composition containing endolucanase III from trichoderma ssp
US5525507A (en) * 1990-10-05 1996-06-11 Genencor International, Inc. Methods for treating cotton-containing fabric with cellulase composition containing endoglucanase component and which is free of all CBH I component
US5246853A (en) * 1990-10-05 1993-09-21 Genencor International, Inc. Method for treating cotton-containing fabric with a cellulase composition containing endoglucanase components and which composition is free of exo-cellobiohydrolase I
CA2093422C (fr) * 1990-10-05 2001-04-03 Genencor International, Inc. Compositions detergentes contenant des compositions de type cellulase a faible teneur en cbh i
US5328841A (en) * 1990-10-05 1994-07-12 Genencor International, Inc. Methods for isolating EG III cellulase component and EG III cellulase in polyethylene glycol using inorganic salt and polyethylene glycol
US5654193A (en) * 1990-10-05 1997-08-05 Genencor International, Inc. Methods for treating cotton containing fabrics with cellulase
US5650322A (en) * 1990-10-05 1997-07-22 Genencor International, Inc. Methods for stonewashing fabrics using endoglucanases
WO1992010581A1 (fr) † 1990-12-10 1992-06-25 Genencor International, Inc. SACCHARIFICATION AMELIOREE DE CELLULOSE PAR CLONAGE ET AMPLIFICATION DU GENE DE β-GLUCOSIDASE DE TRICHODERMA REESEI
WO1992016633A1 (fr) * 1991-03-22 1992-10-01 Novo Nordisk A/S Procede de production de chymosine
JPH07506404A (ja) * 1992-05-01 1995-07-13 ジェネンコア　インターナショナル　インコーポレーテッド 綿含有織物をｃｂｈ　ｉが多いセルラーゼで処理する方法
JPH09505201A (ja) * 1992-07-31 1997-05-27 パンラブス インコーポレイテッド 組換え細胞、ｄｎａ構造、ベクター及びフィチン酸塩分解酵素を任意の比率で発現する方法
US5665585A (en) * 1992-09-03 1997-09-09 Alko-Yhiot Oy Recombinant production of glucoamylase P in trichoderma
GB9400623D0 (en) * 1994-01-14 1994-03-09 Univ Leeds Exploitation of the cellulase enzyme complex of neurospora
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US7816129B2 (en) 1994-07-29 2010-10-19 Ab Enzymes Gmbh Production and secretion of proteins of bacterial origin in filamentous fungi
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5700686A (en) * 1995-06-06 1997-12-23 Iogen Corporation Protease-treated and purified cellulase compositions and methods for reducing backstaining during enzymatic stonewashing
DE69628652T3 (de) 1995-09-08 2012-05-03 Genentech, Inc. Vegf-verwandtes protein
ATE307887T1 (de) 1996-01-08 2005-11-15 Genentech Inc Ob-rezeptor und liganden
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
DE69737457T2 (de) 1997-01-31 2007-11-29 Genentech, Inc., South San Francisco O-fukosyltransferase
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
EP2338915A3 (fr) 1997-04-07 2011-10-12 Genentech, Inc. Anticorps anti-VEGF
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CA2301942C (fr) 1997-08-27 2011-05-31 Chiron Corporation Mimetiques moleculaires des epitopes b meningococciques
EP2014770A3 (fr) 1997-10-29 2009-02-18 Genentech, Inc. Polypeptide secrété à induction par WNT-1 WISP-2
ATE409225T1 (de) 1997-10-29 2008-10-15 Genentech Inc Durch wnt-1 induzierbare gene
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP3112468A1 (fr) 1998-05-15 2017-01-04 Genentech, Inc. Polypeptides allogéniques il-17 et utilisations thérapeutiques
EP1865061A3 (fr) 1998-05-15 2007-12-19 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
NZ508878A (en) 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
JP2002527066A (ja) 1998-10-15 2002-08-27 カイロン コーポレイション 転移性乳癌および結腸癌調節遺伝子
EP1950300A3 (fr) 1998-11-18 2011-03-23 Genentech, Inc. Variantes d'anticorps avec une affinité de liaison plus élevée en comparaison aux anticorps parents
AU2367600A (en) 1998-12-16 2000-07-03 Chiron Corporation Human cyclin-dependent kinase ((hpnqalre))
EP2075335A3 (fr) 1998-12-22 2009-09-30 Genentech, Inc. Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1978029A3 (fr) 1999-06-15 2008-10-15 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
CA2376596C (fr) 1999-06-25 2009-10-06 Genentech, Inc. Anticorps anti-erbb2 humanises et traitement a l'aide de ces anticorps
CA2383642C (fr) 1999-10-14 2014-03-25 Clontech Laboratories, Inc. Chromophores/fluorophores issus d'anthozoaires et methodes d'utilisation
EP1672070A3 (fr) 1999-12-01 2006-10-04 Genentech, Inc. Polypeptides secrétés et transmembranaires et acides nucléiques codant pour ceux-ci
DK1897944T3 (da) 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
EP1985701B1 (fr) 2000-01-10 2012-05-30 Novartis Vaccines and Diagnostics, Inc. Gène s'exprimant par action différentielle dans le cancer du sein
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
EP2275549A1 (fr) 2000-06-23 2011-01-19 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
CA2648048A1 (fr) 2000-06-23 2002-01-03 Genentech, Inc. Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
EP2287296A1 (fr) 2000-06-26 2011-02-23 Novozymes A/S Enzyme lipolytique
PT1303293E (pt) 2000-07-27 2009-03-11 Genentech Inc Administração sequencial de cpt-11 e polipéptido apo-2l
EP2014298A3 (fr) 2000-08-24 2009-10-07 Genentech, Inc. Polypeptides d'interleukine-22, acides nucléiques les codant et procédés de traitement des troubles pancréatiques
EP1944317A3 (fr) 2000-09-01 2008-09-17 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
US7456001B2 (en) 2000-09-05 2008-11-25 Novozymes A/S Lipoxygenase
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
FI120310B (fi) 2001-02-13 2009-09-15 Valtion Teknillinen Parannettu menetelmä erittyvien proteiinien tuottamiseksi sienissä
MXPA03008590A (es) 2001-03-22 2003-12-08 Novo Nordisk Healthcare Ag Derivados del factor vii de coagulacion.
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
CA2444735C (fr) 2001-04-20 2012-10-23 Novozymes A/S Lipoxygenase
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2633171C (fr) 2001-06-20 2012-11-20 Genentech, Inc. Compositions et procedes destines au diagnostic et au traitement de tumeurs
PL368972A1 (en) 2001-08-29 2005-04-04 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
EP1487877B1 (fr) 2001-09-18 2010-10-27 Genentech, Inc. Compositions et procedes pour le diagnostic de tumeurs
BR0212818A (pt) 2001-09-27 2004-10-05 Novo Nordisk Healthcare Ag Polipeptìdeo de fator vii, construção de polionucletìdeo, célula hospedeira, animal transgênico, planta transgênica, método para produzir o polipeptìdeo de fator vii composição farmacêutica, uso de um polipeptìdeo de fator vii, e, método para o tratamento de distúrbios do sangramento em um sujeito ou para o aprimoramento do sistema hemostático normal
EP2042196B1 (fr) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelage et glycoconjugation de facteur stimulant les colonies de granulocytes (G-CSF)
WO2003088808A2 (fr) 2002-04-16 2003-10-30 Genentech, Inc. Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
AU2002357322A1 (en) 2001-12-19 2003-07-09 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
NZ533933A (en) 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
EP2388265A1 (fr) 2002-02-22 2011-11-23 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
MXPA04012243A (es) 2002-06-07 2005-02-25 Genentech Inc Composiciones y metodos para l diagnostico y tratamiento de tumores.
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
SI1543038T2 (sl) 2002-09-11 2020-12-31 Genentech, Inc. Čiščenje proteinov
EP2116551A1 (fr) 2002-09-11 2009-11-11 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2004024097A2 (fr) 2002-09-16 2004-03-25 Genentech, Inc. Compositions et methodes de traitement de maladies de nature immune
AU2003279084A1 (en) 2002-09-25 2004-04-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2006516094A (ja) 2002-11-08 2006-06-22 ジェネンテック・インコーポレーテッド ナチュラルキラー細胞関連疾患の治療のための組成物と方法
EP1572116A4 (fr) 2002-11-26 2007-12-12 Genentech Inc Compositions et procedes destines au traitement de maladies de nature immune
EP3263596A1 (fr) 2002-12-16 2018-01-03 Genentech, Inc. Variantes de l'immunoglobuline et leurs utilisations
CA2513113A1 (fr) 2003-01-23 2004-08-05 Genentech, Inc. Procedes de production d'anticoprs humanises et d'amelioration du rendement d'anticorps ou de fragments de liaison d'antigenes en culture cellulaire
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
EP2055189A1 (fr) 2003-04-09 2009-05-06 Neose Technologies, Inc. Méthode de glycopegylation et proteines/peptides produits au moyen de ces méthodes
EP1620551B1 (fr) 2003-04-28 2013-09-18 Novozymes A/S Phospholipase et son procede de production
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
PL2784084T5 (pl) 2003-07-08 2024-12-02 Novartis Pharma Ag Przeciwciała antagonistyczne heterologicznych polipeptydów il-17a/f
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005019258A2 (fr) 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
SI2295073T1 (sl) 2003-11-17 2014-07-31 Genentech, Inc. Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
CN102174490B (zh) 2003-11-21 2016-09-28 丹尼斯科美国公司 颗粒淀粉水解酶在木霉菌中的表达和从颗粒淀粉底物产生葡萄糖的方法
DK2311873T3 (en) 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
EP2327724A3 (fr) 2004-02-02 2011-07-27 Ambrx, Inc. Polypeptides d'hormone de croissance humaine et leur utilisations
EP2354222A1 (fr) 2004-03-25 2011-08-10 Genencor International, Inc. Protéine de fusion de cellulase et construction de fusion de cellulose hétérologue la codant
US8097445B2 (en) 2004-03-25 2012-01-17 Danisco Us Inc. Exo-endo cellulase fusion protein
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
HRP20110657T1 (hr) 2004-03-30 2011-10-31 Glaxo Group Limited Imunoglobulin koji se veže na osm
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
EP1732944B1 (fr) 2004-04-07 2012-09-05 The University of Chicago Proteines monomeres fluorescentes rouges
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US7332319B2 (en) 2004-05-27 2008-02-19 Genencor International, Inc. Heterologous alpha amylase expression in Aspergillus
AU2005249422B2 (en) 2004-05-27 2011-03-17 Genencor International, Inc. Acid-stable alpha amylases having granular starch hydrolyzing activity and enzyme compositions
CN1981037B (zh) 2004-05-27 2011-08-31 金克克国际有限公司 白曲霉酸稳定性α淀粉酶的异源表达和在颗粒淀粉水解中的应用
US7413887B2 (en) 2004-05-27 2008-08-19 Genecor International, Inc. Trichoderma reesei glucoamylase and homologs thereof
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2006014729A2 (fr) 2004-07-20 2006-02-09 Genentech, Inc. Inhibiteurs de la proteine 4 de type angiopoietine, combinaisons correspondantes et leur utilisation
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
FI118339B (fi) 2004-09-21 2007-10-15 Ab Enzymes Oy Uusi lakkaasientsyymi ja sen käyttö
CA2586313C (fr) 2004-11-10 2016-03-08 Diadexus, Inc. Compositions d'anticorps anti-ovr110 et methodes d'utilisation correspondantes
EP1828224B1 (fr) 2004-12-22 2016-04-06 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
EP1841793B1 (fr) 2005-01-07 2010-03-31 Diadexus, Inc. Compositions d'anticorps ovr110 et techniques d'utilisation
ZA200706858B (en) 2005-02-18 2008-10-29 Genencor Int Polypeptides having alpha-amylase and granular starch hydrolyzing activity
US7488848B2 (en) 2005-03-21 2009-02-10 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
EP2314668B1 (fr) 2005-04-12 2016-11-09 Danisco US Inc. Mutants inactivés génétiques avec une production de protéine altérée
US7741093B2 (en) 2005-04-29 2010-06-22 Ab Enzymes Oy Cellulases and their uses
EP3214095B1 (fr) 2005-05-12 2019-12-11 ZymoGenetics, Inc. Compositions et procédés pour moduler les réponses immunologiques
CA2610709A1 (fr) 2005-06-06 2006-12-14 Genentech, Inc. Nouvelles disruptions geniques, nouvelles compositions et nouveaux procedes s'y rapportant
US7931902B2 (en) 2005-08-15 2011-04-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007053732A2 (fr) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Polymorphismes des promoteurs du gene blys et leur utilisation dans des procedes de diagnostic
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
EP1951890A4 (fr) 2005-11-16 2009-06-24 Ambrx Inc Procedes et compositions comprenant des acides amines non naturels
EP3023497A1 (fr) 2005-11-18 2016-05-25 Glenmark Pharmaceuticals S.A. Anticorps anti-integrine alpha-2 et leurs utilisations
WO2007081608A2 (fr) 2005-11-21 2007-07-19 Genentech, Inc. Nouvelles dissociations de gènes, compositions et procédés les concernant
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
ES2637008T3 (es) 2005-12-22 2017-10-10 Ab Enzymes Oy Enzimas nuevas
US7256032B2 (en) 2005-12-22 2007-08-14 Ab Enzymes Oy Enzymes
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
EP2389947A1 (fr) 2006-03-23 2011-11-30 Novartis AG Thérapeutique anticorps antigène de cellules anti-tumorales
WO2007126455A2 (fr) 2006-04-05 2007-11-08 Genentech, Inc. Méthode d'utilisation du boc/cdo pour moduler l'émission des signaux du hedgehog
KR20140071452A (ko) 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
US7361487B2 (en) 2006-04-13 2008-04-22 Ab Enzymes Oy Enzyme fusion proteins and their use
EP2082645A1 (fr) 2006-04-19 2009-07-29 Genentech, Inc. Nouvelle dislocation de gènes, compositions et procédés correspondants
EP2027291A2 (fr) 2006-04-27 2009-02-25 Pikamab, Inc. Procédés et compositions pour la thérapie par anticorps
EP2024393A2 (fr) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Anticorps neutralisants dirigés contre les virus de la grippe
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
WO2007149567A2 (fr) 2006-06-21 2007-12-27 Musc Foundation For Research Development Ciblage du facteur h du système complémentaire destiné au traitement de maladies
CN101484471B (zh) 2006-06-30 2013-11-06 诺沃-诺迪斯克有限公司 抗-nkg2a抗体及其用途
US20080026376A1 (en) 2006-07-11 2008-01-31 Huaming Wang KEX2 cleavage regions of recombinant fusion proteins
AR062435A1 (es) 2006-08-18 2008-11-05 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
CN101522893B (zh) 2006-10-10 2014-07-09 丹尼斯科美国公司 具有改变性质的葡糖淀粉酶变体
BRPI0718118A2 (pt) 2006-10-27 2017-05-30 Lpath Inc composições e métodos para ligação de sphingosine-1-fosfato
EP2083862A4 (fr) 2006-10-27 2012-09-19 Lpath Inc Compositions et procédés pour traiter des maladies et des troubles oculaires
CA2668208C (fr) 2006-11-02 2017-09-12 Daniel J. Capon Immunoglobulines hybrides presentant des parties mobiles
ES2437110T3 (es) 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
CA2670471A1 (fr) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Substances therapeutiques a base de proteines modifiees ciblees sur des recepteurs de tyrosine kinases, dont l'igf-ir
US8444971B2 (en) 2006-11-27 2013-05-21 Diadexus, Inc. OVR110 antibody compositions and methods of use
KR101519672B1 (ko) 2006-12-07 2015-05-29 노파르티스 아게 Ｅｐｈｂ３에 대한 길항제 항체
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
US20080220498A1 (en) 2007-03-06 2008-09-11 Cervin Marguerite A Variant Buttiauxella sp. phytases having altered properties
US8143046B2 (en) 2007-02-07 2012-03-27 Danisco Us Inc., Genencor Division Variant Buttiauxella sp. phytases having altered properties
CA2676790A1 (fr) 2007-02-22 2008-08-28 Genentech, Inc. Methode de detection d'une maladie intestinale inflammatoire
JP5167286B2 (ja) 2007-03-14 2013-03-21 ダニスコ・ユーエス・インク、ジェネンコー・ディビジョン トリコデルマ・レセイ（ＴＲＩＣＨＯＤＥＲＭＡＲＥＥＳＥＩ）α−アミラーゼはマルトース産生酵素である。
CA2682147C (fr) 2007-03-30 2017-08-08 Ambrx, Inc. Polypeptides fgf-21 modifies, et leurs utilisations
DK2147104T3 (en) 2007-05-21 2015-12-14 Danisco Us Inc USING A ASPARAGINPROTEASE- (NSP24) SIGNAL SEQUENCE FOR heterologous protein EXPRESSION
EP2164992B1 (fr) 2007-05-30 2016-05-04 Lpath, Inc. Compositions et procédés pour lier de l'acide lysophosphatidique
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
BRPI0812767A2 (pt) 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2009031992A1 (fr) * 2007-09-04 2009-03-12 Elizabeth Varriano-Marston Procédé de contrôle de qualité de bananes par l'emballage
WO2009035500A1 (fr) 2007-09-12 2009-03-19 Danisco Us Inc., Genencor Division Promoteur de trichoderma
KR101662622B1 (ko) 2007-10-04 2016-10-05 지모제넥틱스, 인코포레이티드 Ｂ7 패밀리 구성원 ｚＢ7Ｈ6 및 관련된 조성물 및 방법
US8592194B2 (en) 2007-10-09 2013-11-26 Danisco Us Inc. Glucoamylase variants with altered properties
CA3069361C (fr) 2007-10-09 2023-11-28 Danisco Us Inc. Variants de glucoamylase presentant des proprietes modifiees
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
CN101889025B (zh) 2007-10-30 2013-11-13 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
WO2009059305A2 (fr) 2007-11-01 2009-05-07 The University Of Chicago Protéines fluorescentes rouges avec expression bactérienne amplifiée, luminosité accrue et agrégation réduite
US8158762B2 (en) 2007-11-08 2012-04-17 Genentech, Inc. Anti-factor B antibodies and their uses
NZ585500A (en) 2007-11-12 2012-06-29 Theraclone Sciences Inc Antibodies which bind to an epitope in the extracellular domain of the matrix 2 ectodomain polypeptide of an influenza virus
EP3323889B1 (fr) 2007-11-20 2020-03-25 Danisco US Inc. Variantes de la glucoamylase ayant des propriétés altérées
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
WO2009073511A2 (fr) 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphismes du gène blys et utilisation dans des procédés diagnostiques
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
CN105368764B (zh) 2007-12-13 2019-03-12 丹尼斯科美国公司 用于生产异戊二烯的组合物和方法
CN101918545A (zh) 2008-01-02 2010-12-15 丹尼斯科美国公司 应用嗜糖假单胞菌g4-淀粉酶和其变体获得乙醇的无葡糖淀粉酶的方法
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
EP2628753A1 (fr) 2008-01-24 2013-08-21 Novo Nordisk A/S Anticorps monoclonal NKG2A antihumain humanisé
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
CN101945996A (zh) 2008-02-11 2011-01-12 丹尼斯科美国公司 来自里氏木霉的具有微生物裂解活性的酶
AU2009223688B2 (en) 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
WO2009121004A2 (fr) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Molécules neutralisantes d'antigènes viraux
EP3208612B1 (fr) 2008-04-09 2019-09-18 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
EP2283124B1 (fr) 2008-04-18 2016-05-25 Danisco US Inc. Variants de phytase de buttiauxella sp
WO2009132220A2 (fr) 2008-04-23 2009-10-29 Danisco Us Inc. Variants d’isoprène synthases améliorant la production microbienne d’isoprène
RU2553517C2 (ru) 2008-05-06 2015-06-20 Дженентек, Инк. Варианты crig с созревшей аффинностью
MX318543B (es) 2008-07-02 2014-03-18 Danisco Us Inc Composiciones y metodos para producir isopreno libre de hidrocarburos de c5 bajo condicion de desacoplamiento y/o intervalos de operacion seguros.
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
MX2011001506A (es) 2008-08-14 2011-03-15 Genentech Inc Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena.
AR073279A1 (es) 2008-09-05 2010-10-28 TransAlgae Ltd Resistencia a herbicida para mantener cultivos axenicos de algas por manipulacion genetica
EP2344629B1 (fr) 2008-09-15 2018-01-24 Danisco US Inc. Systèmes utilisant une culture de cellules pour la production d isoprène
CA2737223A1 (fr) 2008-09-15 2010-03-18 Danisco Us Inc. Reduction des emissions de dioxyde de carbone pendant la production d'isoprene par fermentation
EP2340312A2 (fr) 2008-09-15 2011-07-06 Danisco US Inc. Conversion de dérivés de prényle en isoprène
WO2010031062A1 (fr) 2008-09-15 2010-03-18 Danisco Us Inc. Production augmentée d’isoprène utilisant la voie du mévalonate inférieur archéenne
WO2010034015A2 (fr) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulation de la voie de complément alternative
PE20110480A1 (es) 2008-09-26 2011-07-01 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
MX2011003272A (es) 2008-09-26 2011-04-28 Ambrx Inc Polipeptidos de eritropoyetina animal modificados y sus usos.
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
WO2010048446A2 (fr) 2008-10-22 2010-04-29 Genentech, Inc. Modulation de la dégénérescence d'axons
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
EA201190002A1 (ru) 2008-11-06 2012-04-30 Гленмарк Фармасьютикалс С.А. Лечение антителами к интегрину альфа-2
DK2358873T4 (en) 2008-12-15 2018-05-28 Danisco Us Inc HYBRID ALPHA AMYLASER
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
FI20086236A0 (fi) 2008-12-23 2008-12-23 Valtion Teknillinen Heksuronihapon konversio heksarihapoksi
FI122029B (fi) 2008-12-30 2011-07-29 Ab Enzymes Oy Sieniperäiset endoglukanaasit, niiden tuotto ja käyttö
MY161071A (en) 2008-12-30 2017-04-14 Danisco Us Inc Methods of producing isoprene and a co-product
WO2010078376A2 (fr) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Anticorps conjugués à un polymère spécifiques de fc et leur utilisation en diagnostic
CA2748314C (fr) 2009-02-03 2018-10-02 Amunix Operating Inc. Polypeptides recombinants etendus et compositions les comprenant
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
WO2010120561A1 (fr) 2009-04-01 2010-10-21 Genentech, Inc. Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
AU2010238770A1 (en) 2009-04-23 2011-11-03 Danisco Us Inc. Three-dimensional structure of isoprene synthase and its use thereof for generating variants
CN102459340A (zh) 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
FI121711B (fi) 2009-04-30 2011-03-15 Ab Enzymes Oy Sieniperäinen seriiniproteaasi ja sen käyttö
FI121712B (fi) 2009-04-30 2011-03-15 Ab Enzymes Oy Uusi sieniperäinen proteaasi ja sen käyttö
EP3473711B1 (fr) 2009-05-19 2020-11-04 DuPont Nutrition Biosciences ApS Polypeptides d'amylase
JP2012527473A (ja) 2009-05-20 2012-11-08 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
SI2440241T1 (sl) 2009-06-08 2017-11-30 Amunix Operating Inc. Polipeptidni rastni hormoni in postopki za njihovo izdelavo in uporabo
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
TWI434921B (zh) 2009-06-17 2014-04-21 Danisco Us Inc 從生物異戊二烯組合物製造燃料成分之方法及系統
TW201412988A (zh) 2009-06-17 2014-04-01 Danisco Us Inc 使用ｄｘｐ及ｍｖａ途徑之改良之異戊二烯製造
FI121851B (fi) 2009-07-08 2011-05-13 Ab Enzymes Oy Sieniperäinen proteaasi ja sen käyttö
US20110117603A1 (en) 2009-07-15 2011-05-19 Abbott Laboratories Enhancement of cellular production through mechanotransduction
US20120282285A1 (en) 2009-07-17 2012-11-08 Rigshospitalet Masp isoforms as inhibitors of complement activation
US8765431B2 (en) 2009-07-23 2014-07-01 The Regents Of The University Of Michigan Method for enzymatic production of decarboxylated polyketides and fatty acids
RU2567803C2 (ru) 2009-07-31 2015-11-10 Дженентек, Инк. ИНГИБИРОВАНИЕ МЕТАСТАЗИРОВАНИЯ ОПУХОЛИ ПРИ ПОМОЩИ АНТАГОНИСТОВ Bv8 ИЛИ G-CSF
AR077942A1 (es) 2009-08-19 2011-10-05 Danisco Variantes de glucoamilasa
CN102712915B (zh) 2009-08-19 2014-12-10 丹尼斯科美国公司 具有改良比活和/或热稳定性的葡糖淀粉酶的组合变体
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
JP5787891B2 (ja) 2009-09-01 2015-09-30 ジェネンテック， インコーポレイテッド 改変されたプロテインａ溶離による向上したタンパク質精製
DK2473522T3 (en) 2009-09-02 2016-11-28 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CN102597775A (zh) 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
MX368790B (es) 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
ES2813398T3 (es) 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
CA2778483A1 (fr) 2009-10-22 2011-04-28 Genentech, Inc. Modulation de la degenerescence d'axones
US8697386B2 (en) 2009-10-22 2014-04-15 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056497A1 (fr) 2009-10-26 2011-05-12 Genentech, Inc. Compositions de récepteur de l'activine de type iib et leurs méthodes d'utilisation
WO2011056502A1 (fr) 2009-10-26 2011-05-12 Genentech, Inc. Compositions du gene recepteur de proteine morphogenetique osseuse type ii et procedes d'utilisation
WO2011056494A1 (fr) 2009-10-26 2011-05-12 Genentech, Inc. Combinaisons d'antagonistes de la kinase-1 du type récepteur de l'activine et d'antagonistes vegfr3
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
KR20120103587A (ko) 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
BR112012012750A2 (pt) 2009-11-30 2020-08-11 Genentech Inc anticorpo isolado, célula, ácido nucleíco isolado e método
ES2583259T3 (es) 2009-12-01 2016-09-20 Novo Nordisk A/S Nuevas liasas alfa-amidantes de peptidil alfa-hidroxiglicina
JP5818805B2 (ja) 2009-12-11 2015-11-18 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ−ｃ抗体及びその使用方法
WO2011080050A2 (fr) 2009-12-11 2011-07-07 Novartis Ag Molécules de liaison
CN104193798A (zh) 2009-12-18 2014-12-10 Csl有限公司 纯化多肽的方法
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
JP6214161B2 (ja) 2009-12-21 2017-10-18 ジェネンテック， インコーポレイテッド 抗体製剤
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
FI122937B (fi) 2009-12-30 2012-09-14 Roal Oy Menetelmä selluloosamateriaalin käsittelemiseksi sekä tässä käyttökelpoiset CBH II/Cel6A entsyymit
MX339083B (es) 2010-01-28 2016-04-01 Glaxo Group Ltd Proteinas de enlace a cd127.
TWI429453B (zh) 2010-02-23 2014-03-11 建南德克公司 抗tat419抗體及其用途
US8975376B2 (en) 2010-02-23 2015-03-10 Sanofi Anti-alpha2 integrin antibodies and their uses
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
CA2791841C (fr) 2010-03-05 2023-01-03 Rigshospitalet Molecules chimeriques inhibitrices d'activation du complement
WO2011120993A1 (fr) 2010-03-29 2011-10-06 Danisco A/S Polypeptides présentant une activité transgalactosylase
BR112012024713B1 (pt) 2010-03-31 2021-02-17 Boehringer Ingelheim International Gmbh anticorpo humanizado, seus usos e composição farmacêutica que o compreende
EP2552967A4 (fr) 2010-04-02 2014-10-08 Amunix Operating Inc Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
WO2011133931A1 (fr) 2010-04-22 2011-10-27 Genentech, Inc. Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire
MX342239B (es) 2010-05-03 2016-09-21 Genentech Inc * Composiciones y metodos para el diagnostico y tratamiento de tumores.
PL2576580T3 (pl) 2010-05-28 2017-03-31 F.Hoffmann-La Roche Ag Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
AU2011261161A1 (en) 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
US8933282B2 (en) 2010-06-17 2015-01-13 Danisco Us Inc. Fuel compositions comprising isoprene derivatives
EP2585094B1 (fr) 2010-06-25 2018-08-01 INSERM - Institut National de la Santé et de la Recherche Médicale Procédés et compositions pharmaceutiques pour le traitement d'infections des voies respiratoires
BR112013001637A2 (pt) 2010-07-22 2016-05-24 Glaxosmithkline Biolog Sa proteína ligadora de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para produção de proteína ligadora de antígeno, e para detectar mage-a3 e/ou mage-a6 em tecido de humano fixado com formalina e infiltrado em parafina.
CA2807558A1 (fr) 2010-08-06 2012-02-09 Danisco Us Inc. Production d'isoprene dans des conditions de ph neutre
BR112013001179A2 (pt) 2010-08-06 2016-05-31 Danisco Us Inc sacrificação e fermentação em ph neutro.
WO2012021786A2 (fr) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Compositions d'anticorps anti-hemagglutinine et ses méthodes d'utilisation
EP2420250A1 (fr) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anticorps anti-syndecan-4
RU2013110844A (ru) 2010-08-13 2014-09-20 Дженентек, Инк. АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
EP2608682B1 (fr) 2010-08-24 2017-12-13 Danisco US Inc. Procédé de préparation d'une barre snack comportant un concentré de protéine de riz à basse température
CA3249351A1 (fr) 2010-08-31 2025-07-03 Theraclone Sciences, Inc. Anticorps neutralisants anti-virus de l'immunodéficience humaine (vih)
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
AU2011302522A1 (en) 2010-09-15 2013-05-02 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
CA2810909A1 (fr) 2010-09-20 2012-03-29 Abbvie Inc. Purification d'anticorps par chromatographie a lit mobile simule
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
KR101687060B1 (ko) 2010-10-08 2016-12-15 상하이 켁신 바이오테크 씨오., 엘티디. 모에신 조절제 및 그의 용도
EP2624856B1 (fr) 2010-10-08 2016-12-14 Shanghai Kexin Biotech Co., Ltd Fragments de la moésine pour leur utilisation dans le diagnostic de la thrombocytopénie immunitaire
EP2624852B1 (fr) 2010-10-08 2016-12-14 Shanghai Kexin Biotech Co., Ltd Utilisations diagnostiques et thérapeutiques de fragments de la moésine
EP2624855B1 (fr) 2010-10-08 2016-12-14 Shanghai Kexin Biotech Co., Ltd Fragments de la moésine associés à l'anémie aplasique
KR101641756B1 (ko) 2010-10-08 2016-07-21 상하이 켁신 바이오테크 씨오., 엘티디. 모에신 단편 및 그의 용도
CA2816306A1 (fr) 2010-10-27 2012-05-03 Danisco Us Inc. Variantes d'isoprene synthase pour l'augmentation de la production d'isoprene
FI123942B (fi) 2010-10-29 2013-12-31 Ab Enzymes Oy Sieniperäisen seriiniproteaasin variantteja
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
EP2635905A2 (fr) 2010-11-05 2013-09-11 AbbVie Inc. Criblage de compléments se révélant efficace en vue de la mise au point de milieux chimiquement définis pour cultures cellulaires
EP2640831A1 (fr) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Agents de neutralisation du virus de la grippe qui imitent le site de liaison d'un anticorps de neutralisation du virus de la grippe
JP2014502844A (ja) 2010-12-22 2014-02-06 ダニスコ・ユーエス・インク 組み換え細胞による五炭糖の生物学的生産
WO2012083370A1 (fr) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Anticorps modifié présentant une demi-vie améliorée
BR112013018316A2 (pt) 2010-12-22 2018-09-11 Danisco Us Inc composições e métodos para produção aprimorada de isopreno usando dois tipos de enzimas ispg
JP2014506580A (ja) 2011-02-14 2014-03-17 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
WO2012122512A1 (fr) 2011-03-10 2012-09-13 Hco Antibody, Inc. Production recombinante de mélanges d'anticorps monocaténaires
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
SG193402A1 (en) 2011-03-15 2013-10-30 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of influenza
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
WO2012128810A1 (fr) 2011-03-23 2012-09-27 Abbott Laboratories Procédés et systèmes pour l'analyse d'échantillons protéiques
EP3412309A1 (fr) 2011-03-31 2018-12-12 F. Hoffmann-La Roche AG Procédés d'administration d'antagonistes de l'intégrine bêta7
FI123425B (fi) 2011-03-31 2013-04-30 Ab Enzymes Oy Proteaasientsyymi ja sen käytöt
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
BR112013027170A2 (pt) 2011-04-29 2017-06-20 Danisco Us Inc processo em ph único para liquefação e sacarificação de amido para xaropes de glicose de densidade alta
WO2012158818A2 (fr) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
SG195253A1 (en) 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
AP2014007415A0 (en) 2011-07-11 2014-02-28 Glenmark Pharmaceuticals Sa Antibodies that bind to OX40 and their uses
WO2013022799A1 (fr) 2011-08-05 2013-02-14 Danisco Us Inc. Production d'isoprénoïdes dans des conditions de ph neutre
CA2842481A1 (fr) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition de l'angiogenese dans les tumeurs refractaires
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
EP2755675B1 (fr) 2011-09-12 2018-06-06 Amunix Operating Inc. Compositions de peptide-2 de type glucagon et leurs procédés de fabrication et d'utilisation
MX2014003313A (es) 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
WO2013067028A1 (fr) 2011-10-31 2013-05-10 Bp Corporation North America Inc. Utilisation de promoteurs mammaliens dans des champignons filamenteux
US9249418B2 (en) 2011-10-31 2016-02-02 Bp Corporation North America Inc. Use of plant promoters in filamentous fungi
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
BR112014013205A2 (pt) 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN104471068A (zh) 2011-12-16 2015-03-25 布拉斯科南美公司(巴西) 经修饰的微生物和使用其制造丁二烯的方法
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
WO2013091903A1 (fr) 2011-12-22 2013-06-27 Novo Nordisk A/S Anticorps anti-canal crac
HK1203823A1 (en) 2012-01-19 2015-11-06 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
AU2013217986B2 (en) 2012-02-09 2017-04-27 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (fr) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Proteines de facteur viii de recombinaison
EP2820047B1 (fr) 2012-03-01 2018-04-25 Amgen Research (Munich) GmbH Molécules de liaison à un polypeptide à longue durée de vie
WO2013158275A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de culture cellulaire pour réduire des espèces acides
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013163606A1 (fr) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antagonistes de facteur de croissance endothélial vasculaire et méthodes destinées à leur utilisation
US9163263B2 (en) 2012-05-02 2015-10-20 The Goodyear Tire & Rubber Company Identification of isoprene synthase variants with improved properties for the production of isoprene
EP4039275A1 (fr) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anticorps anti-il-23p19
TW201348246A (zh) 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之人類、人類化或嵌合抗體之新穎純化
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2013182686A1 (fr) 2012-06-08 2013-12-12 Dupont Nutrition Biosciences Aps Polypeptides présentant une activité de transgalactosylation
JP2015524808A (ja) 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法
WO2014018079A1 (fr) 2012-07-25 2014-01-30 University Of Cincinnati Procédé pour traiter des troubles d'hyperglycémie au moyen d'apolipoprotéine aiv
MX2015002099A (es) 2012-08-22 2015-05-11 Dupont Nutrition Biosci Aps Variantes que tienen actividad glucoamilasa.
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
CN104704118A (zh) 2012-10-15 2015-06-10 诺和诺德保健Ag（股份有限公司） 凝血因子vii多肽
EA201591153A1 (ru) 2013-01-02 2016-01-29 Гленмарк Фармасьютикалс С.А. Антитела, связывающиеся с tl1a, и их применение
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
EP2948478B1 (fr) 2013-01-25 2019-04-03 Amgen Inc. Anticorps ciblant cdh19 pour un mélanome
PL2968467T3 (pl) 2013-03-13 2020-10-19 F. Hoffmann-La Roche Ag Preparaty o zmniejszonym utlenianiu
IL269947B (en) 2013-03-13 2022-08-01 Genentech Inc Formulations with reduced oxidation
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
CN110538322A (zh) 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
US20140271633A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Mammalian cell culture performance through surfactant supplementation of feed media
WO2014159554A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Composition d'espèces faiblement acides et leurs méthodes de production utilisant la chromatographie de déplacement
WO2014142882A1 (fr) 2013-03-14 2014-09-18 Abbvie Inc. Purification de protéine utilisant une chromatographie de déplacement
CA2926301A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Compositions d'especes faiblement acides et leurs procedes de production et d'utilisation
WO2014145768A2 (fr) 2013-03-15 2014-09-18 Bp Corporation North America Inc. Utilisation de 5' utr non fongiques dans des champignons filamenteux
WO2014140358A1 (fr) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Molécules de liaison à chaîne simple comprenant l'abp à l'extrémité n-terminale
SI2970875T2 (sl) 2013-03-15 2026-03-31 F. Hoffmann-La Roche Ag Sestavki celičnih kultur z antioksidanti in postopki za proizvodnjo polipeptidov
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2014140368A1 (fr) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Constructions d'anticorps pour m2 et cd3 de grippe
EP2968544A4 (fr) 2013-03-15 2016-10-12 Hoffmann La Roche Support de culture cellulaire et procédés de production d'anticorps
US11220556B2 (en) 2013-03-15 2022-01-11 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
WO2014146575A1 (fr) 2013-03-19 2014-09-25 Beijing Shenogen Pharma Group Ltd. Anticorps et procédés permettant de traiter des maladies associées aux récepteurs des œstrogènes
KR102175688B1 (ko) 2013-03-27 2020-11-06 제넨테크, 인크. 베타7 인테그린 길항제를 사용하는 위장 염증성 장애의 치료를 평가하기 위한 바이오마커의 사용
LT3004162T (lt) 2013-05-31 2020-06-10 Genentech, Inc. Antikūnai prieš ląstelės sienelės teicho rūgštį ir konjugatai
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
MX375378B (es) 2013-09-27 2025-03-06 Genentech Inc Formulaciones de anticuerpos anti-pdl1.
US10203327B2 (en) 2013-11-05 2019-02-12 Novartis Ag Organic compounds
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
EP4165999A1 (fr) 2013-12-11 2023-04-19 DuPont Nutrition Biosciences ApS Procédé de préparation d'un produit laitier ayant une teneur stable en galacto-oligosaccharides(s)
WO2015095404A2 (fr) 2013-12-17 2015-06-25 Genentech, Inc. Procédés de traitement de cancers à l'aide d'antagonistes se liant à l'axe pd-1 et de taxanes
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
MX2016007885A (es) 2013-12-17 2017-01-11 Genentech Inc Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
JP2017502672A (ja) 2013-12-30 2017-01-26 メディシナル バイオコンバージェンス リサーチ センター 抗ｋｒｓモノクロナル抗体及びこれの用途
WO2015116902A1 (fr) 2014-01-31 2015-08-06 Genentech, Inc. Récepteurs couplés aux protéines g dans la signalisation hedgehog
WO2016039801A1 (fr) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Nouveaux anticorps anti-baff
JP6736467B2 (ja) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド 平滑化変異体及びその使用方法
NZ724904A (en) 2014-03-14 2023-04-28 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
BR112016021739B1 (pt) 2014-03-25 2021-11-03 Genentech, Inc Método para preparar um poloxâmero para uso em um meio de cultura de célula
KR20220065091A (ko) 2014-03-27 2022-05-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
EP3149187B1 (fr) 2014-05-30 2020-04-29 Braskem S.A. Micro-organismes modifiés comprenant un système optimisé pour l'utilisation d'oligosaccharides et procédés pour les utiliser
WO2015198320A1 (fr) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Procédés de purification d'anticorps
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (fr) 2014-07-09 2016-01-14 Abbvie Inc. Procédés pour moduler le profil de glycosylation de protéines recombinantes au moyen de sucres non utilisés couramment
EP3172339A1 (fr) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarqueurs utiles dans le traitement de maladies associées à l'il-23a
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
AU2015295242B2 (en) 2014-07-31 2020-10-22 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
WO2016059602A2 (fr) 2014-10-16 2016-04-21 Glaxo Group Limited Méthodes de traitement du cancer et compositions associées
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
WO2016071504A1 (fr) 2014-11-07 2016-05-12 Dupont Nutrition Biosciences Aps CELLULE HÔTE RECOMBINANTE EXPRIMANT UNE ACTIVITÉ β-GALACTOSIDASE ET/OU DE TRANSGALACTOSYLATION DÉFICIENTE EN MANNANASE, EN CELLULASE ET EN PECTINASE
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
HK1243931A1 (zh) 2014-12-03 2018-07-27 F. Hoffmann-La Roche Ag 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
CN107206081A (zh) 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
CA2975875A1 (fr) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened et methodes d'utilisation de celui-ci
BR112017016897A2 (pt) 2015-02-09 2018-03-27 Danisco Us Inc cepas fúngicas e métodos de uso
KR20170120601A (ko) 2015-02-26 2017-10-31 제넨테크, 인크. 인테그린 베타7 길항제 및 크론병을 치료하는 방법
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
WO2016144773A1 (fr) 2015-03-06 2016-09-15 Abbvie Inc. Glycoprotéines arabinosylées
EP3770171A1 (fr) 2015-04-03 2021-01-27 XOMA Technology Ltd. Traitement du cancer à l'aide d'inhibiteurs de tgf-bêta et pd-1
EP3283109A1 (fr) 2015-04-14 2018-02-21 Boehringer Ingelheim International GmbH Méthodes de traitement de maladies
ES2945313T3 (es) 2015-04-17 2023-06-30 Amgen Res Munich Gmbh Construcciones de anticuerpos biespecificos para CDH3 y CD3
ES2929531T3 (es) 2015-05-22 2022-11-30 Dupont Nutrition Biosci Aps Acetolactato descarboxilasa
EP3763827A1 (fr) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Méthylation de promoteur de pd-l1 dans le cancer
JP6896650B2 (ja) 2015-06-17 2021-06-30 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
KR102055396B1 (ko) 2015-08-11 2019-12-12 우시 바이올로직스 (케이만) 인코포레이티드 신규한 항-pd-1 항체
CA2997213C (fr) 2015-09-02 2021-01-19 Dupont Nutrition Biosciences Aps Glycoside hydrolases et leur utilisation dans la prevention et/ou le traitement d'une infection pathogene chez un animal
EP3896080A1 (fr) 2015-09-07 2021-10-20 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Nouveau récepteur de type igfr et son utilisations
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
HRP20250951T1 (hr) 2015-12-30 2025-10-10 F. Hoffmann-La Roche Ag Formulacije sa smanjenom razgradnjom polisorbata
EP3397243A1 (fr) 2015-12-30 2018-11-07 H. Hoffnabb-La Roche Ag Utilisation de dérivés du tryptophane pour formulations protéiques
CN116063544A (zh) 2016-02-03 2023-05-05 安进研发（慕尼黑）股份有限公司 Bcma和cd3双特异性t细胞接合抗体构建体
EP3411404B1 (fr) 2016-02-03 2022-11-09 Amgen Research (Munich) GmbH Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド 突然変異体スムースンド及びその使用方法
CN116196412A (zh) 2016-03-15 2023-06-02 中外制药株式会社 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
CN108779180B (zh) 2016-03-23 2020-10-16 迈博斯生物医药(苏州)有限公司 新型抗-pd-l1抗体
EP3560956A3 (fr) 2016-04-15 2020-01-01 Boehringer Ingelheim International GmbH Procédés de traitement de maladies inflammatoires
WO2017181143A1 (fr) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Utilisation d'il-22 pour le traitement de l'entérocolite nécrosante
US10851159B2 (en) 2016-06-02 2020-12-01 Bloom Diagnostics Ag Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
BR112018077458A2 (pt) 2016-06-30 2019-04-02 Danisco Us Inc. proteases aspárticas
WO2018026748A1 (fr) 2016-08-01 2018-02-08 Xoma (Us) Llc Anticorps du récepteur 1 de l'hormone de parathyroïde (pth1r) et leurs utilisations
WO2018029124A1 (fr) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Méthodes thérapeutiques et de diagnostic du cancer
CA3037083A1 (fr) 2016-09-16 2018-03-22 Dupont Nutrition Biosciences Aps Variants d'acetolactate decarboxylase ayant une activite specifique amelioree
EP3515950A4 (fr) 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. Nouveaux anticorps anti-pcsk9
RU2763378C2 (ru) 2016-09-23 2021-12-28 ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС ПРИМЕНЕНИЕ АКТИВНЫХ ПРИ НИЗКОМ ЗНАЧЕНИИ pH АЛЬФА-1,4/1,6-ГЛИКОЗИДГИДРОЛАЗ В КАЧЕСТВЕ КОРМОВОЙ ДОБАВКИ ДЛЯ ЖВАЧНЫХ ЖИВОТНЫХ ДЛЯ УЛУЧШЕНИЯ ПЕРЕВАРИВАНИЯ КРАХМАЛА
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
EP3523415A1 (fr) 2016-10-04 2019-08-14 Danisco US Inc. Production de protéines dans des cellules fongiques filamenteuses en l'absence de substrats inducteurs
EP3526252A2 (fr) 2016-10-14 2019-08-21 Boehringer Ingelheim International GmbH Méthodes de traitement de maladies avec anticorps il-23a
WO2018075474A1 (fr) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions et méthodes de traitement d'une lésion du système nerveux central
WO2018093752A1 (fr) 2016-11-15 2018-05-24 Danisco Us Inc. Champignons filamenteux à production améliorée de protéines
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
EP3574007A1 (fr) 2017-01-30 2019-12-04 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Nouveau récepteur igfr de type 2 et ses utilisations
TN2019000225A1 (en) 2017-02-02 2021-01-07 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
WO2018152496A1 (fr) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions et méthodes de diagnostic et de traitement de l'infection par le virus zika
WO2018164876A1 (fr) 2017-03-06 2018-09-13 Dupont Nutrition Biosciences Aps Nouvelles fucosidases fongiques et leur utilisation dans la prévention et/ou le traitement d'une infection pathogène chez un animal
EP4095161A1 (fr) 2017-03-15 2022-11-30 Tsinghua University Nouveaux anticorps anti-trkb
WO2018182284A1 (fr) 2017-03-27 2018-10-04 재단법인 의약바이오컨버젼스연구단 Anticorps se liant spécifiquement à la région n-terminale de la lysyl-arnt synthétase exposée sur une membrane cellulaire
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
EP4230649A3 (fr) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Anticorps et procédés de diagnostic et de traitement d'infection par le virus d'epstein barr
MX2019013142A (es) 2017-05-05 2019-12-16 Amgen Inc Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
US11827669B2 (en) 2017-07-19 2023-11-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
AU2018337142B2 (en) 2017-09-22 2025-07-03 Wuxi Biologics Ireland Limited. Novel bispecific CD3/CD19 polypeptide complexes
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
KR20250111232A (ko) 2017-12-11 2025-07-22 암젠 인크 이중특이적 항체 생성물의 연속 제조 공정
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
KR20200123155A (ko) 2018-02-21 2020-10-28 셀진 코포레이션 Bcma-결합 항체 및 이의 용도
US12202894B2 (en) 2018-03-20 2025-01-21 WuXi Biologics Ireland Limited Anti-TIM-3 antibodies
KR102340989B1 (ko) 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
EP3774916A2 (fr) 2018-04-06 2021-02-17 Biolegend, Inc. Agents anti-tétraspanine 33 et compositions et procédés pour la fabrication et l'utilisation de ces agents
WO2019213416A1 (fr) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Anticorps et méthodes de diagnostic, de prévention et de traitement d'infection par le virus d'epstein barr
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
CN112585166A (zh) 2018-06-23 2021-03-30 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
WO2020006347A1 (fr) 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anticorps anti-cd40 destinés à être utilisés dans le traitement d'une maladie auto-immune
US20210278406A1 (en) 2018-07-13 2021-09-09 Varct Diagnostic Aps Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa
CA3106537A1 (fr) 2018-08-08 2020-02-13 Genentech, Inc. Utilisation de derives du tryptophane pour de l-methionine pour une formulation proteique
EP3847196A4 (fr) 2018-09-07 2023-01-04 ITabMed (HK) Limited Protéines de liaison à un antigène bispécifiques et leurs utilisations
KR102739487B1 (ko) 2018-09-21 2024-12-10 제넨테크, 인크. 3중-음성 유방암에 대한 진단 방법
EP3856343A1 (fr) 2018-09-25 2021-08-04 Biolegend, Inc. Agents anti-tlr9 et compositions et procédés pour les préparer et les utiliser
US11505614B2 (en) 2018-09-28 2022-11-22 Amgen Inc. Antibodies binding to soluble BCMA
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
EP3636735B1 (fr) 2018-10-12 2024-03-27 AB Enzymes Oy Variant d'une protease et son l'utilisation
EP3870614A1 (fr) 2018-10-23 2021-09-01 GlyCardial Diagnostics, S.L. Anticorps spécifiques de l'apoj glycosylée et leurs utilisations
WO2020132810A1 (fr) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Protéines multispécifiques de liaison à l'antigène pouvant se lier à cd19 et cd3, et leur utilisation
KR20220004979A (ko) 2019-03-27 2022-01-12 유엠씨 우트레크트 홀딩 비.브이. 조작된 iga 항체 및 사용 방법
MX2021013671A (es) 2019-05-09 2021-12-10 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares.
WO2020238730A1 (fr) 2019-05-24 2020-12-03 三优生物医药(上海)有限公司 Nouvelle molécule de liaison cldn18.2
MX2021014644A (es) 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
TWI877179B (zh) 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
US20220268787A1 (en) 2019-07-18 2022-08-25 Jw Bioscience Antibody specifically binding to wrs protein, and use thereof
WO2021038296A2 (fr) 2019-08-27 2021-03-04 Tonix Pharma Holdings Limited Polypeptides tff2 modifiés
US12577297B2 (en) 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations
AU2020345787A1 (en) 2019-09-10 2022-03-24 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
KR102442204B1 (ko) 2019-09-20 2022-09-08 경북대학교 산학협력단 Cox2 단백질의 아세틸화 검출용 항체 및 이의 용도
TWI859339B (zh) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
JP7793519B2 (ja) 2019-12-19 2026-01-05 ビーエーエスエフ ソシエタス・ヨーロピア ファインケミカルを生成する際の空時収率、炭素変換効率、及び炭素基質適応性の増加
KR20220119408A (ko) 2019-12-20 2022-08-29 바스프 에스이 터펜의 독성 감소 및 미생물에서 생산 잠재성 증가
EP4093771A1 (fr) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinaisons de constructions d'anticorps et d'inhibiteurs du syndrome de libération de cytokine et leurs utilisations
EP4106794A4 (fr) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd Procédés de traitement d'une maladie du greffon contre l'hôte
EP4118120A4 (fr) 2020-03-12 2024-04-17 Immune-ONC Therapeutics, Inc. Nouveaux anticorps anti-lilrb4 et produits dérivés
KR20220155338A (ko) 2020-03-19 2022-11-22 암젠 인크 뮤신 17에 대한 항체 및 이의 용도
CN113461817B (zh) 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
EP4632063A3 (fr) 2020-04-15 2025-10-22 Genentech, Inc. Atténuation des pertes de cuivre
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1
BR112022024221A2 (pt) 2020-06-02 2022-12-20 Arcus Biosciences Inc Anticorpos para tigit
JP7785023B2 (ja) 2020-06-15 2025-12-12 サレプタ セラピューティクス， インコーポレイテッド アデノ関連ウイルス抗体及びそのフラグメント
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
EP3939999A1 (fr) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Anticorps neutralisant la sous-unité alpha du récepteur de l'interleukine 11 (il11ra) et leurs utilisations
WO2022093641A1 (fr) 2020-10-30 2022-05-05 BioLegend, Inc. Agents anti-nkg2a et compositions et méthodes de production et d'utilisation de ceux-ci
WO2022093640A1 (fr) 2020-10-30 2022-05-05 BioLegend, Inc. Agents anti-nkg2c et compositions et méthodes de production et d'utilisation de ceux-ci
EP4240767A1 (fr) 2020-11-06 2023-09-13 Amgen Inc. Constructions polypeptidiques se liant à cd3
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
IL301926A (en) 2020-11-06 2023-06-01 Amgen Inc Antigen binding domain with reduced clipping rate
CN112480248B (zh) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
JP2024500747A (ja) 2020-12-18 2024-01-10 キニクサ ファーマシューティカルズ， リミテッド タンパク質組成物ならびにそれを産生及び使用するための方法
MX2023011690A (es) 2021-04-02 2023-12-15 Amgen Inc Construcciones de unión a mageb2.
EP4373855A1 (fr) 2021-07-23 2024-05-29 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anticorps ciblant igfr-l1 et leurs utilisations
WO2023105087A1 (fr) 2021-12-10 2023-06-15 Tubulis Gmbh Nouveaux anticorps flt3 et conjugués anticorps-médicament à base de ceux-ci, méthodes thérapeutiques et leurs utilisations en combinaison avec des inhibiteurs de tyrosine kinase
IL313655A (en) 2021-12-22 2024-08-01 Boehringer Ingelheim Int Anti-C3 antibodies and their antigen-binding fragments and their uses for the treatment of eyes or eye diseases
KR20230098953A (ko) 2021-12-27 2023-07-04 경북대학교 산학협력단 Asm에 특이적으로 결합하는 항체 및 이의 용도
JP2025505131A (ja) 2022-01-29 2025-02-21 ペキン ユニバーシティ ファースト ホスピタル ＩｇＡプロテアーゼトランケート、ＩｇＡプロテアーゼトランケートを含む融合タンパク質及びその用途
EP4238988A1 (fr) 2022-03-01 2023-09-06 Consejo Superior De Investigaciones Científicas Anticorps dirigés contre le sars-cov-2 et leurs utilisations
JP2025509274A (ja) 2022-03-09 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー 治療用タンパク質の一過性発現
AU2023330110A1 (en) 2022-08-22 2025-03-06 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
US20260083841A1 (en) 2022-09-14 2026-03-26 Amgen Inc. Bispecific Molecule Stabilizing Composition
WO2024083953A1 (fr) 2022-10-18 2024-04-25 Tubulis Gmbh Nouvel anticorps anti-tpbg et conjugués anticorps-médicament basés sur celui-ci, procédés thérapeutiques et utilisations dudit anticorps
CN120166939A (zh) 2022-10-18 2025-06-17 Tubulis 股份有限公司 新型抗napi2b抗体和基于该抗体的抗体-药物-偶联物、治疗方法及其用途
CN120476149A (zh) 2022-12-23 2025-08-12 成都恩沐生物科技有限公司 靶向gprc5d的多特异性多肽复合物
WO2024131962A1 (fr) 2022-12-23 2024-06-27 成都恩沐生物科技有限公司 Nouvel anticorps anti-gprc5d
WO2024243217A1 (fr) 2023-05-25 2024-11-28 BioLegend, Inc. Anticorps liant ceacam6 et fragments de liaison à l'antigène de ceux-ci
MX2025014635A (es) 2023-06-14 2026-02-03 Amgen Inc Moleculas captadoras de enmascaramiento de celulas t
WO2025036848A1 (fr) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps anti-muc16 et utilisations
WO2025043134A1 (fr) 2023-08-24 2025-02-27 Rezolute, Inc. Formulations à haute concentration pour anticorps anti-récepteur de l'insuline et leurs utilisations
CN121816366A (zh) 2023-09-27 2026-04-07 百进公司 抗gpc4抗体
TW202523694A (zh) 2023-11-17 2025-06-16 中國大陸商上海藥明生物技術有限公司 抗muc16抗體及其用途
WO2025144974A1 (fr) 2023-12-29 2025-07-03 Absci Corporation Variants de domaine fc pour extension de demi-vie et leurs utilisations
WO2025157132A1 (fr) 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps multispécifiques ciblant cd3, cd19 et cd20 et leurs utilisations
WO2025171378A1 (fr) 2024-02-09 2025-08-14 Rezolute, Inc. Modulation du récepteur de l'insuline pour hyperinsulinisme associé à une tumeur
TW202602919A (zh) 2024-03-01 2026-01-16 德商百靈佳殷格翰國際股份有限公司 結締組織生長因子(ctgf)之抗體及其用途
US20250313650A1 (en) 2024-04-04 2025-10-09 BioLegend, Inc. Chi3l1 binding antibodies and antigen binding fragments thereof
WO2025230843A2 (fr) 2024-05-01 2025-11-06 BioLegend, Inc. Anticorps se liant au kir et leurs fragments se liant à l'antigène
US20260092096A1 (en) 2024-05-14 2026-04-02 35Pharma Inc. Activin receptor type iib variants and uses thereof
WO2026006472A2 (fr) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions d'anticorps il-1r1 et leurs procédés de production et d'utilisation
WO2026039642A1 (fr) 2024-08-16 2026-02-19 Ardeagen Corporation Conjugués d'anticorps anti-mésothéline et leurs procédés d'utilisation
WO2026075999A2 (fr) 2024-10-01 2026-04-09 Sarepta Therapeutics, Inc. Dystrophine et anticorps de micro-dystrophine et fragments associés

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338400C (fr) * 1983-08-31 1996-06-18 David H. Gelfand Cellulases fongiques recombinantes
DE3650202T3 (de) * 1985-08-29 2004-06-03 Genencor International, Inc., South San Francisco Expression von heterologen Polypeptiden in filamentösen Pilzen, Verfahren zu deren Herstellung und Vektoren zu deren Herstellung.
JPS62175183A (ja) * 1985-08-29 1987-07-31 ジエネンコ−　インコ−ポレ−テツド 繊維状菌類中に発現する異種ポリペプチドとその製造方法及びその製造のためのベクタ−

Also Published As

Publication number Publication date
DK175814B1 (da) 2005-03-07
NO871785D0 (no) 1987-04-29
JP2769305B2 (ja) 1998-06-25
IE871149L (en) 1987-10-30
ES2056817T5 (es) 2002-05-01
DE3786592T3 (de) 2002-05-29
JPH08173156A (ja) 1996-07-09
GB8610600D0 (en) 1986-06-04
FI871908L (fi) 1987-10-31
NO871785L (no) 1987-11-02
EP0244234B1 (fr) 1993-07-21
EP0244234A2 (fr) 1987-11-04
DK219087A (da) 1987-10-31
JPS6394981A (ja) 1988-04-26
ATE91714T1 (de) 1993-08-15
EP0244234B2 (fr) 2001-11-07
IE60428B1 (en) 1994-07-13
JP2702924B2 (ja) 1998-01-26
EP0244234A3 (en) 1988-10-12
DK219087D0 (da) 1987-04-29
DE3786592D1 (de) 1993-08-26
ES2056817T3 (es) 1994-10-16
DE3786592T2 (de) 1993-11-04
FI871908A0 (fi) 1987-04-29

Similar Documents

Publication Publication Date Title
FI108358B (fi) Trichoderman transformointi
Nakari-Set� l� et al. Production of Trichoderma reesei cellulases on glucose-containing media
CA1341532C (fr) Polypeptides heterologues exprimes dans les champignons filamenteux, leur procede de preparation ainsi que vecteurs pour leur preparation
US5874276A (en) Cellulase enzymes and systems for their expressions
FI117388B (fi) Valintamerkkigeenittömät hiivakannat, menetelmä niiden valmistamiseksi ja näiden kantojen käyttö
US5364770A (en) Heterologous polypeptides expressed in aspergillus
EP0272277B1 (fr) EXPRESSION DE GENES EUCARYOTIQUES SUPERIEURS DANS L'$i(ASPERGILLUS)
US5298405A (en) Enzyme preparations with recombinantly-altered cellulose profiles and methods for their production
US10876103B2 (en) Protein production in filamentous fungal cells in the absence of inducing substrates
HK1003579B (en) Heterologous polypeptide expressed in filamentous fungi, processes for their preparation, and vectors for their preparation
JPH08507695A (ja) Ｅｇ ▲ｉｉｉ▼セルラーゼの精製及び分子クローニング
KR20020093932A (ko) 사상균 크리소스포리움 분야에서의 발현 조절 서열 및발현 생성물
Kurzatkowski et al. Glucose-induced secretion of Trichoderma reesei xylanases
JP3522744B2 (ja) セルラーゼタンパク質を含有する水性混合物からキシラナーゼの豊富な組成物を単離する方法
US5610034A (en) Immunoglobulin production by trichoderma
CN107109424A (zh) 真菌宿主菌株、dna构建体及使用方法
AU657911B2 (en) Immunoglobulin production by (Trichoderma)
FI114482B (fi) Erittyvien proteiinien lisääntynyt tuotanto eukaryoottisilla yhdistelmäsoluilla
FI116529B (fi) Menetelmiä oleellisesti puhtaan EG III -sellulaasin tuottamiseksi alkoholia käyttäen
KR20250102093A (ko) 향상된 단백질 생산성 표현형을 포함하는 사상 진균 균주 및 이의 방법
Podkaminer et al. Heterologous protein expression in Hypocrea jecorina: A historical perspective and new developments

Legal Events

Date Code Title Description
FG Patent granted

Owner name: ALTIA GROUP OY

MA Patent expired